Novartis gets FDA orphan drug status for branaplam to treat Huntington’s disease

This article was originally published here

Branaplam has been demonstrated to decrease levels of mutant huntingtin protein in preclinical models, said Novartis. Based on the results, Novartis aims to begin a development programme for

The post Novartis gets FDA orphan drug status for branaplam to treat Huntington’s disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply